These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22952885)

  • 1. Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach.
    Ouchida M; Kanzaki H; Ito S; Hanafusa H; Jitsumori Y; Tamaru S; Shimizu K
    PLoS One; 2012; 7(8):e44095. PubMed ID: 22952885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression.
    Yamamoto K; Ito S; Hanafusa H; Shimizu K; Ouchida M
    PLoS One; 2015; 10(9):e0137887. PubMed ID: 26367773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of miR-21 targets in breast cancer cells using a quantitative proteomic approach.
    Yang Y; Chaerkady R; Beer MA; Mendell JT; Pandey A
    Proteomics; 2009 Mar; 9(5):1374-84. PubMed ID: 19253296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of direct targets for the miR-17-92 cluster by proteomic analysis.
    Kanzaki H; Ito S; Hanafusa H; Jitsumori Y; Tamaru S; Shimizu K; Ouchida M
    Proteomics; 2011 Sep; 11(17):3531-9. PubMed ID: 21751348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
    BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
    Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
    J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact.
    Leivonen SK; Rokka A; Ostling P; Kohonen P; Corthals GL; Kallioniemi O; Perälä M
    Mol Cell Proteomics; 2011 Jul; 10(7):M110.005322. PubMed ID: 21512034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of
    Meng Q; Wang L; Lv Y; Wu J; Shi W
    Cancer Biother Radiopharm; 2021 Feb; 36(1):23-35. PubMed ID: 32319789
    [No Abstract]   [Full Text] [Related]  

  • 9. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24.
    Cao Y; Yu SL; Wang Y; Guo GY; Ding Q; An RH
    Tumour Biol; 2011 Feb; 32(1):179-88. PubMed ID: 20857258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential regulatory network in the PSG10P/miR-19a-3p/IL1RAP pathway is possibly involved in preeclampsia pathogenesis.
    Wang N; Li R; Xue M
    J Cell Mol Med; 2019 Feb; 23(2):852-864. PubMed ID: 30370628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying targets of miR-143 using a SILAC-based proteomic approach.
    Yang Y; Chaerkady R; Kandasamy K; Huang TC; Selvan LD; Dwivedi SB; Kent OA; Mendell JT; Pandey A
    Mol Biosyst; 2010 Oct; 6(10):1873-82. PubMed ID: 20544124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics.
    Yan GR; Xu SH; Tan ZL; Liu L; He QY
    Proteomics; 2011 Mar; 11(5):912-20. PubMed ID: 21271679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
    Farazi TA; Ten Hoeve JJ; Brown M; Mihailovic A; Horlings HM; van de Vijver MJ; Tuschl T; Wessels LF
    Genome Biol; 2014 Jan; 15(1):R9. PubMed ID: 24398324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
    Zhong S; Li W; Chen Z; Xu J; Zhao J
    Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combined approach identifies three mRNAs that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7.
    Wang C; Gao C; Zhuang JL; Ding C; Wang Y
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2127-36. PubMed ID: 22864815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells.
    Yu X; Zhang X; Dhakal IB; Beggs M; Kadlubar S; Luo D
    BMC Cancer; 2012 Jan; 12():29. PubMed ID: 22260523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-6744-5p promotes anoikis in breast cancer and directly targets NAT1 enzyme.
    Malagobadan S; Ho CS; Nagoor NH
    Cancer Biol Med; 2020 Feb; 17(1):101-111. PubMed ID: 32296579
    [No Abstract]   [Full Text] [Related]  

  • 18. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth.
    Yan LX; Wu QN; Zhang Y; Li YY; Liao DZ; Hou JH; Fu J; Zeng MS; Yun JP; Wu QL; Zeng YX; Shao JY
    Breast Cancer Res; 2011 Jan; 13(1):R2. PubMed ID: 21219636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
    Sun FD; Wang PC; Luan RL; Zou SH; Du X
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.